Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

BACKGROUND: To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs) previously treated with ranibizumab (Lucenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurana, Rahul N., Chang, Louis K., Bansal, Alok S., Palmer, James D., Wu, Chengqing, Wieland, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463635/
https://www.ncbi.nlm.nih.gov/pubmed/31016030
http://dx.doi.org/10.1186/s40942-019-0159-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463635/
https://www.ncbi.nlm.nih.gov/pubmed/31016030
http://dx.doi.org/10.1186/s40942-019-0159-x

Ejemplares similares